| Citation: |
CHEN Dandan, LUO Junhui, ZHANG Haitao, XIA Cui. Clinical effect of Mudan Granules combined with pentoxifylline in treatment of type 2 diabetes mellitus combined with early renal disease[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 116-120. DOI: 10.7619/jcmp.20243133
|
To investigate the clinical effect of Mudan Granules combined with pentoxifylline in the treatment of type 2 diabetes mellitus (T2DM) with early renal disease and analyze its impact on the Toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) signaling pathway.
A total of 164 patients with T2DM and early renal disease admitted to the Second People's Hospital of Hunan Province between May 2022 and October 2023 were enrolled and randomly divided into observation group(n=82) and control group (n=82) using a random number table in a 1-to-1 ratio. The control group received pentoxifylline treatment, while the observation group received Mudan granules combined with pentoxifylline. The clinical effects and changes in renal function indicators[serum creatinine (SCr), urea nitrogen, urinary albumin-to-creatinine ratio (UACR)], TLR4/NF-κB signaling pathway indicators (TLR4, MyD88, NF-κB mRNA), and inflammation and oxidative stress indicators [C-reactive protein (CRP), glutathione peroxidase (GSH-PX), malondialdehyde (MDA), total antioxidant capacity (TAC), and transforming growth factor β1 (TGF-β1)] before and after treatment were compared between the two groups.
The total effective rate in the observation group was 97.56%, which was higher than 89.02% in the control group (P<0.05). At 6 and 12 weeks after treatment, the levels of SCr, urea nitrogen, and UACR in both groups decreased compared with those before treatment, and the levels of these indicators in the observation group were lower than those in the control group (P<0.05). At 6 and 12 weeks after treatment, the levels of TLR4, MyD88, and NF-κB mRNA in both groups decreased compared with those before treatment, and the levels of these indicators in the observation group were lower than those in the control group (P<0.05). At 6 and 12 weeks after treatment, the levels of GSH-PX and TAC in both groups increased, while the levels of CRP, MDA, and TGF-β1 decreased compared with those before treatment. The levels of GSH-PX and TAC in the observation group were higher than those in the control group, while the levels of CRP and MDA were lower (P<0.05).
Mudan Granules combined with pentoxifylline in the treatment of T2DM with early renal disease can improve renal function to a certain extent, regulate the TLR4/NF-κB signaling pathway, and reduce inflammation and oxidative stress responses, which is beneficial for disease control.
| [1] |
CHRIST-CRAIN M, WINZELER B, REFARDT J. Diagnosis and management of diabetes insipidus for the internist: an update[J]. J Intern Med, 2021, 290(1): 73-87. doi: 10.1111/joim.13261
|
| [2] |
THIPSAWAT S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: a review of the literature[J]. Diab Vasc Dis Res, 2021, 18(6): 14791641211058856. doi: 10.1177/14791641211058856
|
| [3] |
郑海龙, 陈小盼, 那涵, 等. 己酮可可碱注射液联合羟苯磺酸钙片治疗糖尿病周围神经病变患者的临床研究[J]. 中国临床药理学杂志, 2023, 39(7): 951-955.
|
| [4] |
MOOSAIE F, RABIZADEH S, FALLAHZADEH A, et al. Effects of pentoxifylline on serum markers of diabetic nephropathy in Type2 diabetes[J]. Diabetes Ther, 2022, 13(5): 1023-1036. doi: 10.1007/s13300-022-01250-y
|
| [5] |
BELL D S H. Are the protean effects of pentoxifylline in the therapy of diabetes and its complications still relevant[J]. Diabetes Ther, 2021, 12(12): 3025-3035. doi: 10.1007/s13300-021-01168-x
|
| [6] |
王宁, 于世家, 刘阳. 木丹颗粒治疗糖尿病并下肢动脉硬化闭塞症临床研究[J]. 辽宁中医药大学学报, 2022, 24(5): 203-208.
|
| [7] |
魏从兵, 黄启亮, 贾云, 等. 针灸联合木丹颗粒治疗糖尿病周围神经病变患者临床观察[J]. 湖北中医药大学学报, 2022, 24(5): 98-100.
|
| [8] |
闫文, 屈杰, 陈丽名, 等. 中药基于TLR4/NF-κB信号通路干预糖尿病肾病炎症反应的研究进展[J]. 现代中西医结合杂志, 2023, 32(22): 3186-3190. doi: 10.3969/j.issn.1008-8849.2023.22.023
|
| [9] |
中华医学会, 中华医学会临床药学分会, 中华医学会杂志社, 等. 2型糖尿病基层合理用药指南[J]. 中华全科医师杂志, 2021, 20(6): 615-630. doi: 10.3760/cma.j.cn114798-20210318-00257
|
| [10] |
中华医学会肾脏病学分会专家组. 糖尿病肾脏疾病临床诊疗中国指南[J]. 中华肾脏病杂志, 2021, 37(3): 255-304. doi: 10.3760/cma.j.cn441217-20201125-00041
|
| [11] |
WANG N, ZHANG C. Recent advances in the management of diabetic kidney disease: slowing progression[J]. Int J Mol Sci, 2024, 25(6): 3086. doi: 10.3390/ijms25063086
|
| [12] |
李凤, 郭力, 蔡利群. 益气养阴通络方联合羟苯磺酸钙对气阴两虚血瘀证糖尿病肾病疗效的影响[J]. 实用临床医药杂志, 2023, 27(15): 40-44. doi: 10.7619/jcmp.20231206
|
| [13] |
张阳, 朱勤, 陈洪宇. 糖尿病肾病氧化炎症发生机制及中医药治疗研究进展[J]. 中国中西医结合肾病杂志, 2022, 23(6): 559-562. doi: 10.3969/j.issn.1009-587X.2022.06.030
|
| [14] |
MARTHA J W, PRANATA R, RAFFAELLO W M, et al. The role of pentoxifylline in preventing contrast-induced nephropathy in coronary angiography/intervention - systematic review, meta-analysis, and meta-regression of randomized controlled trials[J]. Eur Rev Med Pharmacol Sci, 2022, 26(9): 3310-3319.
|
| [15] |
SHAYANPOUR S, MEHRI A, HAYATI F, et al. Determination of pentoxifylline efficacy on microalbuminuria in patients with type-2 diabetes[J]. Recenti Prog Med, 2024, 115(1): 15-20.
|
| [16] |
晏继喜, 查淑娟, 谈欢. 己酮可可碱联合骨髓间充质干细胞对高糖诱导的小鼠肾小球系膜细胞凋亡及氧化应激的影响[J]. 中国药理学与毒理学杂志, 2020, 34(5): 352-358. doi: 10.3867/j.issn.1000-3002.2020.05.004
|
| [17] |
DONATE-CORREA J, SANCHEZ-NIÑO M D, GONZÑLEZ-LUIS A, et al. Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease[J]. Clin Kidney J, 2022, 15(12): 2200-2213. doi: 10.1093/ckj/sfac143
|
| [18] |
王琳, 韩超, 张亚玲, 等. 参芪地黄汤加减结合西医常规疗法治疗Ⅲ期糖尿病肾病气阴两虚证临床研究[J]. 国际中医中药杂志, 2022, 44(4): 384-388. doi: 10.3760/cma.j.cn115398-20210719-00180
|
| [19] |
唐利, 廖常彬, 王强, 等. 糖尿病肾病(Ⅲ~Ⅳ期)气阴两虚血瘀证患者应用益气养阴通络汤治疗效果及作用机制[J]. 中药材, 2022, 45(10): 2507-2511.
|
| [20] |
相洋, 胡相卡, 杨鹤, 等. 基于网络药理学的木丹颗粒治疗糖尿病肾病的作用机制研究[J]. 中国中西医结合肾病杂志, 2023, 24(5): 432-435, 后插7. doi: 10.3969/j.issn.1009-587X.2023.05.019
|
| [21] |
ZHANG L D, CUI X, LIU F M, et al. Clinical comprehensive evaluation of Mudan Granules in treatment of diabetic peripheral neuropathy with Qi-deficiency and collateral stagnation syndrome[J]. China J Chin Mater Med, 2021, 46(23): 6078-6086.
|
| [22] |
岳树香, 甄云凤, 霍丽梅. 木丹颗粒联合西医常规治疗早期糖尿病肾病临床疗效及对患者Toll样受体4/核因子κB、转化生长因子β1/Smad信号通路的影响[J]. 河北中医, 2020, 42(5): 722-726.
|
| [23] |
王帅, 王丽, 于世家. 木丹颗粒联合胰激肽原酶治疗气虚血瘀型早期糖尿病肾病的临床效果[J]. 中国医药, 2023, 18(10): 1547-1551.
|
| [24] |
陈剑平, 李常慧, 黄诗莹, 等. 基于成分表征和网络药理学研究黄芪丹参煎液治疗急性肾损伤的质量标志物[J]. 中国药师, 2022, 25(12): 2079-2086.
|
| [25] |
杜阳, 于清源, 任钧国. 木丹颗粒治疗气虚血瘀证糖尿病周围神经病变的分子机制研究[J]. 世界中西医结合杂志, 2022, 17(3): 509-518.
|
| [26] |
QI M Y, HE Y H, CHENG Y, et al. Icariin ameliorates streptozocin-induced diabetic nephropathy through suppressing the TLR4/NF-κB signal pathway[J]. Food Funct, 2021, 12(3): 1241-1251.
|
| [27] |
邓璇, 王瑜. Toll样受体4与Nod样受体蛋白3炎性小体在糖尿病肾脏疾病中的研究进展[J]. 临床肾脏病杂志, 2022, 22(7): 595-601.
|
| [28] |
AWAD A M, ELSHAER S L, GANGARAJU R, et al. Ameliorative effect of montelukast against STZ induced diabetic nephropathy: targeting HMGB1, TLR4, NF-κB, NLRP3 inflammasome, and autophagy pathways[J]. Inflammopharmacology, 2024, 32(1): 495-508.
|
| [29] |
李莉, 隋亚平, 耿雪静, 等. 胸腺基质淋巴细胞生成素、Toll样受体2和免疫球蛋白E对小儿银屑病湿疹病变的预测价值[J]. 实用临床医药杂志, 2022, 26(7): 124-127. doi: 10.7619/jcmp.20213836
|
| 1. |
殷华芳，沙莎，蔡依玲，于波，刘佳，何佳，孙玲娣，王坚. 宫颈癌放射治疗相关卵巢损伤的分子机制及防治策略研究进展. 实用临床医药杂志. 2024(10): 141-144 .
 本站查看
| |
| 2. |
张玉洲，李晓敏，孙少霖. 蓝萼乙素通过Akt/BAD通路对宫颈癌裸鼠移植瘤生长的影响. 现代药物与临床. 2024(06): 1384-1389 .
| |
| 3. |
沈静，张丽华，徐晶晶，吕萌萌，吴东辰. 卡瑞利珠单抗联合白蛋白结合型紫杉醇对晚期宫颈癌患者肿瘤标志物、免疫功能和血管新生指标的影响. 现代生物医学进展. 2024(13): 2592-2595 .
| |
| 4. |
曾美男. 早期宫颈癌术后不同治疗方法的临床效果分析. 实用妇科内分泌电子杂志. 2023(24): 28-30+85 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: